Lyka Labs Limited (NSE:LYKALABS)
74.50
+1.18 (1.61%)
Jan 28, 2026, 12:48 PM IST
Lyka Labs Revenue
Lyka Labs had revenue of 366.61M INR in the quarter ending September 30, 2025, a decrease of -10.92%. This brings the company's revenue in the last twelve months to 1.33B, up 5.31% year-over-year. In the fiscal year ending March 31, 2025, Lyka Labs had annual revenue of 1.35B with 27.04% growth.
Revenue (ttm)
1.33B
Revenue Growth
+5.31%
P/S Ratio
1.96
Revenue / Employee
2.67M
Employees
499
Market Cap
2.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.35B | 287.16M | 27.04% |
| Mar 31, 2024 | 1.06B | 167.66M | 18.75% |
| Mar 31, 2023 | 894.17M | -950.50M | -51.53% |
| Mar 31, 2022 | 1.84B | 1.16B | 169.25% |
| Mar 31, 2021 | 685.11M | 118.05M | 20.82% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 164.76B |
| Dishman Carbogen Amcis | 27.59B |
| Anthem Biosciences | 20.77B |
| OneSource Specialty Pharma | 14.19B |
| Blue Jet Healthcare | 11.79B |
| Concord Biotech | 11.25B |
| Supriya Lifescience | 7.15B |
| Panacea Biotec | 6.04B |
Lyka Labs News
- 6 months ago - Lyka Labs shares fall 3% as Q1 net profit falls 20% YoY; Check earnings - Business Upturn
- 10 months ago - Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain - Business Upturn